Research Papers: Gerotarget (Focus on Aging):
Agerelated modulation of plasmatic betaGalactosidase activity in healthy subjects and in patients affected by T2DM
PDF | Full Text | How to cite
Liana Spazzafumo1,*, Emanuela Mensà2,*, Giulia Matacchione2,*, Tiziana Galeazzi3, Lucia Zampini3, Rina Recchioni4, Fiorella Marcheselli4, Francesco Prattichizzo5, Roberto Testa6, Roberto Antonicelli7, Paolo Garagnani8,9, Massimo Boemi10, Massimiliano Bonafè8, Anna Rita Bonfigli11, Antonio Domenico Procopio2,4 and Fabiola Olivieri2,4
1 Center of Biostatics, INRCA-IRCCS National Institute, Ancona, Italy
2 Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy
3 Pediatric Division, Department of Clinical Sciences, Università Politecnica delle Marche, Ospedali Riuniti, Presidio Salesi, Ancona, Italy
4 Center of Clinical Pathology and Innovative Therapy, INRCA-IRCCS National Institute, Ancona, Italy
5 Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica, Sesto San Giovanni, Italy
6 Clinical Laboratory and Molecular Diagnostics, INRCA-IRCCS National Institute, Ancona, Italy
7 UTIC-Cardiology INRCA-IRCCS, National Institute, Ancona, Italy
8 Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy
9 Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden
10 Diabetology Unit, INRCA-IRCCS, National Institute, Ancona, Italy
11 Scientific Direction, INRCA-IRCCS, National Institute, Ancona, Italy
* The authors contributed equally to this work
Correspondence to:
Anna Rita Bonfigli, email:
Keywords: cellular senescence; beta galactosidase activity; type 2 diabetes; aging; inflammaging; Gerotarget
Received: August 02, 2017 Accepted: October 04, 2017 Published: October 16, 2017
Abstract
β-Galactosidase (β-Gal) activity has been the most extensively utilized biomarker for the detection of cellular senescence. It can be measured also in plasma, and few recent evidence showed an altered plasmatic β-Gal activity in patients affected by some age-related diseases (ARDs). Since T2DM is one of the most common ARDs, we aimed to investigate if plasmatic β-Gal activity is modulated in T2DM patients and if “age” could affect such modulation. To gain mechanistic insights we paralleled this investigation with the evaluation of β-Gal activity in young and senescent endothelial cells (HUVECs) cultured in normo- and hyper-glycaemic environment.
A significant age-related increase of plasmatic β-Gal activity was observed in healthy subjects (n. 230; 55-87 years), whereas the enzymatic activity was significantly reduced in T2DM patients (n. 230; 55-96 years) compared to healthy subjects.
β-Gal activity detectable both in cells and in the culture medium was significantly increased in senescent cells compared to the younger ones, both under normo- and hyper-glycaemic condition. However, the hyper-glycaemic condition was not associated with an increased β-Gal activity in milieu compared to normo-glycaemic condition.
Overall our data reinforce the notion that plasmatic β-Gal activity could be a systemic biomarker of aging, whereas T2DM patients are characterized by a different age-releated trend.